论文部分内容阅读
目的探讨多发性骨髓瘤血浆suPAR水平的临床特点。方法选取我院2009年1月至2012年12月42例多发性骨髓瘤患者设定为研究组,并选取42例健康者作为对照组,应用ELISA检测方法对其血浆suPAR水平和其他临床指标进行分析。结果和对照组对比,研究组suPAR显著上升(P<0.05),各亚型并未出现统计学差异;suPAR水平和血沉、肌酐、Hb以及临床分期都具有相关性。结论多发性骨髓瘤患者suPAR变化对于病情诊断以及预后都具有重要的临床作用。
Objective To investigate the clinical features of plasma suPAR level in multiple myeloma. Methods Forty-two patients with multiple myeloma from January 2009 to December 2012 in our hospital were selected as the study group and 42 healthy controls were selected as the control group. The level of plasma suPAR and other clinical indexes were determined by ELISA analysis. Results Compared with the control group, suPAR was significantly increased in the study group (P <0.05), and there was no statistical difference in each subtype. The level of suPAR was correlated with ESR, creatinine, Hb and clinical stage. Conclusion The changes of suPAR in patients with multiple myeloma have important clinical value in the diagnosis and prognosis of patients.